MedTrace Logo

Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)

NCT00536692 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2008-04-08

No results posted yet for this study

Summary

This is an open-label study evaluating the safety and tolerability of topical ocular mecamylamine given twice a day in patients with diabetic macular edema (DME). Patients will be treated for 12 weeks.

Conditions

Interventions

DRUG

mecamylamine

topical ocular drops

Sponsors & Collaborators

  • Juvenile Diabetes Research Foundation

    collaborator OTHER

  • CoMentis

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Completion
2008-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00536692 on ClinicalTrials.gov